Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. Largely due to patient lead advocacy for minimally invasive treatment options, high-quality prostate implants have become widely available in the US, Europe, and Japan. The reason that brachytherapy results are reproducible in several different practice settings is because numerous implant quality factors have been defined over the last 20 years, which can be applied objectively to judge the success of the intervention both during and after the procedure. In addition, recent long-term follow-up studies have clarified that the secondary cancer incidence of brachytherapy is not clinically meaningful. In terms of future directions, the study of radiation repair genetics may allow for the counseling physician to better estimate any given patients risk for side effects, thereby substantially reducing the therapeutic uncertainties faced by patients choosing a prostate cancer intervention.
T he use of low dose rate brachytherapy using computerassisted treatment planning confers a reproducible cure rate with a limited side effect profile. 1 The first conception of the transperineal approach using a transrectal ultrasound probe was initially reported by Holm in 1983. Over the last 25 years numerous significant advances have been made, which built on this initial insight. [2] [3] [4] In this review we will first describe the various methods that have evolved relating to a transperineal approach. After this discussion, we will review the efficacy and side effects of prostate brachytherapy.
Outcomes derived from a broad range of brachytherapy experience, including results from large institutions with 20 years of experience, as well as results from groups reporting their initial cases, will be presented. This diversity of excellent results is arguably the main strength of prostate brachytherapy relative to the other available methods for the treatment of localized prostate cancer. Low dose rate brachytherapy pio-neers carefully delineated implant quality factors, which has provided a solid foundation upon which reproducible results are possible across a spectrum of clinical experience. [5] [6] [7] IMPLANT TECHNIQUES
Real Time
In 1990 physicians at the Mount Sinai Medical Center developed the prostate brachytherapy technique termed the real-time method. This technique is heavily reliant on detailed clinical knowledge of the transverse and sagittal ultrasound anatomy of the prostate gland. According to the original inception of this method, an activity per volume table (nomogram) is used to find the proper amount of activity for the seeds to be implanted. Based on the concepts put forth by Patterson and Parker, a peripherally weighted implant can be completed by following a relatively straightforward set of guidelines. 4 The first step, usually performed in the urologist's office, is determination of prostate volume by applying an ellipsoid formula (height ϫ width ϫ length ϫ 0.52). This volume is used to determine the number of seeds and total activity ordered for the patient by referring to a look-up table.
In the operating room, the prostate volume is remeasured using step-section planimetry at 5-mm intervals from base to apex. Three longitudinal measurements (anterior, middle, and posterior) of the prostate are made in the midline to find the average length of the gland; this important step serves as a general guide for the number of seeds to be placed within the periphery and interior of the gland. The suggested seed activities for both I-125 (range 0.3-0.6 mCi) and Pd-103 (1.5-3 U) are titrated as such to give a continuous isodose line with each other if placed no further than 1cm apart. Therefore, a prostate length of 3 cm will require 4 seeds, 1 at both the apex and base and 2 in the middle. A 4-cm length will require 5 seeds and so forth. The number of peripheral needles is determined by taking a circumferential measurement at the prostate's greatest transverse diameter. If the circumference is 12 cm, then at least 12 needles should be used. The final decision on the number of needles and spacing between needles and seeds will be somewhat dependent on the activity per seed selected. A higher activity will allow greater spacing (and therefore fewer needles and seeds) but at a cost of needing to be more conservative with proximity to the urethra and rectum. These simple measurements, in addition to referencing the look-up table, allow one to have a reliable road map for the seed implant without the use of a computer-mediated plan. In addition, it allows the implant team to work from the same set of reproducible assumptions to evaluate new technologies or software innovations. 8, 9 The implantation is intentionally divided into an initial peripheral and subsequent interior phase. Placing the peripheral needles only greatly improves the imaging of the anterior needles and seeds. As this technique is highly dependent on direct visualization of the position of each needle and seed, any interference caused by the interior needles could contribute to an inferior dosimetric outcome. The goal of the interior needle and seed placement is to deliver the dose to the base and apex of the gland, to provide dose escalation if desired, and to supplement any "cold" areas not covered adequately by peripheral seed placement.
The initial phase consists of peripheral needle placement (usually 12-18 needles) just inside the prostate capsule, with approximately 1-cm spacing, using the greatest transverse image of the prostate. During this process, it is important, although not imperative, that bilateral needle symmetry is achieved within the prostate. Although the length of the prostate gland and the number of needles required are known, the precise number of seeds required may need to be adjusted on the basis of the evaluation of the intraoperative treatment plan, which is developed in tandem with placement of the peripheral needles. When centers are first starting utilization of this technique, an even loading of the peripheral needles from base to apex as identified on the sagittal image, which depicts the entire length of the Foley catheter, would be recommended. For centers with experience, integration of the treatment planning computer into the determination of precise needle and seed placement can allow for extremely conformal implants that simultaneously deliver an oncologically optimal dose to the entire gland while avoiding hot spots near the urethra. From a technical standpoint, it is important to also remember that the posterior needles should be placed well beyond the prostate capsule into the prostate parenchyma, at least 5 mm from the capsule and/or 8 mm from the inner rectal mucosa. This will assure that the rectal dose is well within the acceptable range. Generally, 75% of the seeds are placed in the periphery, in accordance with the principles of Paterson and Parker. If one uses an intraoperative treatment planning software system, it is very common, especially in smaller glands Ͻ35cm 3 for 80%-85% of the seeds to be deposited in the periphery of the gland. After insertion of peripheral needles to take into account the effect of edema, prostate deformation, and precise needle position, the images are again recaptured in the treatment planning system and the initial plan is reevaluated in light of the new position of the prostate. This reevaluation serves as an additional opportunity to optimize the implant dosimetrically and to critically evaluate peripheral needle distribution. The radioactive sources are placed individually using the sagittal setting of the probe. It is important for the brachytherapist to identify prostatic anatomy before the placement of the sources by referring often to the midline sagittal image to ensure that probe movement and prostate movement are properly accounted for as the sources are placed throughout the peripheral needles. In addition, during this process the exact seed position is mapped by the dosimetrist using the real-time treatment planning software. If a seed slips or clumps, this event is accounted for and its consequences can be evaluated and adjusted for during the remainder of the implant procedure. 10 For source placement, the Mick applicator (Mick TP-200; Mick Radionuclear Instruments, Mount Vernon, NY) is used. It is important to remember that the prostate is a three-dimensional object in terms of its relations to the bladder, urethra, and rectum. The Mick applicator allows the operator the freedom to place seeds closer together or farther apart from each other as required by an individual's anatomy. This is particularly important for insertion of the peripheral apical seeds. Here the prostate anatomy is best visualized by sagittal imaging, and a mechanistic approach is best avoided to ensure that seeds are not placed into the periprostatic tissue, which at this point consists largely of perirectal musculature. In addition, the treatment planning system allows the brachytherapist to judge in 3 dimensions where he or she is at in relation to the urethra throughout the procedure. For order of needle implantation, it is best to be consistent in approach to allow the dosimetry team to follow the progress of the implant accurately. Generally the needles furthest from the probe are the most difficult to visualize and should be implanted first, with progression toward the posterior needles near the probe. 11 After the entire periphery is implanted, insertion of interior needles is then undertaken, with the remaining 25% of total activity implanted. This is where the treatmentplanning computer is particularly important because it allows another opportunity to ensure the dosimetric quality of the implant. In addition, one can often test new dose distributions by varying needle location to best fit the unique characteristics of the implant to this point. Usually 4 -7 interior needles are used, located at least 5 mm away from the urethra. The purpose of the interior seeds is to adequately cover the base and apex and not necessarily to provide a high amount of radiation to the center. For centers that are beginning an implant program, we advocate internal needle placement in a U-shape around the urethra. As one gains confidence in the procedure and the use of intraoperative treatment planning software, the inner needle distribution can be more variable and continue to fulfill the planned dose constraints ( Fig. 1 ). In addition, at this point the intraoperative dosimetry system may be used to rationalize the use of fewer seeds than originally suggested by the nomogram. It is important to always place at least one seed at the apex and at the base, regardless of what the intraoperative software suggests to ensure adequate 30-day postimplant dosimetry. [12] [13] [14] [15] Patients with biopsy-confirmed seminal vesicle involvement and negative nodal involvement should have vesicles implanted. Deposition of seeds is accomplished through the peripheral needles or through 4 -5 additional needles that are placed in the seminal vesicles after removal of the interior ones. The seeds are placed in the anterior and posterior walls to ensure that the prescription dose cloud covers at least the proximal half of the seminal vesicles. 16, 17 When all seeds are implanted, a dynamic cystogram under fluoroscopy is performed to exclude the possibility of seeds placed in the bladder or in the urethra. If present, these can be removed before the patient is taken to the recovery room.
PREPLAN
After the introduction of image-guided seed deposition with the use of axial transrectal ultrasound by Holm, physicians at the Seattle Prostate Institute refined this original technique by developing the preplanned method of prostate brachytherapy in the mid-1980s. 18 According to this method, a plan is created by the physics staff a few days before the implant by using the transverse transrectal ultrasound images captured in the office. The patient is similarly positioned in the operating room to duplicate the preplan, the predetermined coordinates are identified, and preloaded needles are then placed.
The plan starts with a volume study of the prostate in the urologist's office, where transverse images are generated at 5-mm intervals and carefully outlined with a light pen. Then each of the images is entered into the treatment planning computer software that generates a three-dimensional model of the gland and calculates the position of each seed into the prostate with dose designation. Finally, this plan is used in the operating room where physicians attempt to put the patient in the same position as when the preplan was created, by meticulous duplication of external set-up parameters such as hip and knee angles. Needles are preloaded with spacers and are then inserted by the use of a template through the perineum in the prostate. The transrectal ultrasound probe is not used to direct the seed placement but is used to assist in the re-creation of the preplan and assure that the needles are positioned in the predetermined locations. 19, 20 The implant begins anteriorly and proceeds posteriorly. Each needle is inserted into its preplanned grid location and then is carefully withdrawn, keeping the obturator stationary for the entire row of alternated seeds to be placed in the predetermined position. Loose seeds can also be placed using the Mick applicator, should the clinician identify a potential deficit not encountered by the preplanning team.
When all needles are inserted, a cystoscopy is performed to identify whether any needle was placed in the urethra or bladder. If so, the preloaded strand is removed and reloaded in the needle for repeated insertion.
In their early implantations the Seattle group used uniform placing of seeds throughout the prostate. Later, peripheral deposition was used to avoid high doses to the central part of the gland. In addition, the initial ultrasound probes did not allow for a biplanar view, which meant that when the technique originated, only the transverse image was available, creating the need to rely upon the preplan and identification of a fixed base point from which to implant all sources. The introduction of the biplanar probe improved identification of the apex and base, resulting in improved coverage of the ends of the gland. 21
OTHER TECHNIQUES

Magnetic-Resonance Imaging Guided
In this technique real-time magnetic resonance (MR) imaging is used for performing prostate seed implantation and is described by D'Amico et al 22, 23 as follows. A MRcompatible perineal template is fixed to the MR imaging couch in a way that allows movement of the template in 3 dimensions and an MR imaging unit are used. A rectal obturator is passed through the template and fixed. Through the obturator, intrarectal gas is passed, ending in a rubber tube that fills the rectum. Its function is to fix the prostate and to assure that the rectal wall will stay out of the course of the needles. The seeds are loaded in the periphery.
Axial, coronal, and sagittal images at 5-mm intervals using a MR coil are acquired in a 0.5-Tesla magnetic field. The peripheral zone of the prostate (clinical target volume), prostatic urethra, and anterior rectal wall are identified in each axial slice. Each MR-compatible catheter loading is calculated using an algorithm. The preloaded catheters with seeds are inserted through the template and via the perineum into the prostate. Their position is identified in all 3 planes and compared with the expected location according to the treatment plan. The coronal view provides information to the physician about whether the needle has deviated from its straight path. The same process is repeated for all planned catheters. 24, 25 At the end of the procedure, a cystoscopy is performed for assessment of bladder neck integrity and for identification and removal of any seeds placed in the bladder.
Radioimmunoguided
This technique uses the radiolabeled antibody, In-111 capromab pendetide (ProstaScint), specific for prostate-specific membrane antigen to identify regions within the prostate gland where there is a preponderance of tumor. The singlephoton emission computed tomography images obtained from the ProstaScint scan are fused to pelvis computed tomography imaging; through this fusion areas of increased uptake are identified, and using a preplanned approach, similar to the one outlined above but crafted to intentionally allow the 150% prescription isodose line to cover the areas of high ProstaScint activity. 26, 27 
Robot-Assisted
This technique is in its infancy and has only been described from a feasibility standpoint. Largely because of the relatively few side effects conferred by the procedure in relatively inexperienced hands and the ease with which the technique can be adopted, it is unlikely that this approach will find an indication until its cost has decreased dramatically. 28, 29 
PROSTATE-SPECIFIC ANTIGEN (PSA) CONTROL RATES
Low Risk
Patients with low-risk prostate cancer are particularly well suited for low-dose rate brachytherapy. Although various brachytherapy regimens, including implant alone, implant plus hormonal therapy, and combined implant and external beam radiotherapy (EBRT), have been used for patients with low-risk cancers, it has been the consensus of most brachytherapists, as well as the American Brachytherapy Society, that low-dose rate brachytherapy alone is the optimal regimen to maximize cancer control while minimizing morbidity ( Table 1 ). Of the 7 series listed in the table with 10 years of follow-up, the rate of durable biochemical control ranges from 87% to 94%.
Intermediate Risk
For patients with intermediate-risk prostate cancer, generally those with a Gleason score of 7, a PSA value 10 or a palpable stage T2b tumor, many practitioners have added either hormonal therapy or EBRT to confer a high cure rate. At Mount Sinai, the following treatment algorithm has evolved. The preferred treatment currently for intermediaterisk prostate cancer is the combination of neoadjuvant antiandrogen therapy for a duration of 3 months, followed by a prostate seed implant to a full dose. This regimen has been shown to improve outcomes compared with those with brachytherapy alone. An alternative option is to combine a partial-dose brachytherapy implant with supplemental EBRT to 45 Gy. Generally, at approximately 7 or more years, the reported biochemical control rate ranges from approximately 70% to 95% ( Table 2 ). There is certainly also heterogeneity in this group of patients based upon the definitions of intermediate-risk used as well as the volume of cancer as determined by a pretreatment biopsy. With longer follow-up and improved staging (such as using percent of biopsy involved with the tumor), a brachytherapist should be able to further identify patients with more advanced intermediate-risk fea-tures and determine more precisely which patients would benefit from the addition of EBRT to the prostate only or to the pelvis with or without concurrent adjuvant hormone therapy. This understanding has the potential to bring all treated series to an 80%-90% freedom from biochemical failure rate at and beyond 5 years minimum follow-up.
High Risk
From the early inception of treating prostate cancer with brachytherapy, it became known that patients with high-risk disease faired poorly when treated with a seed implant alone. 53, 54 This knowledge led to the practice of combining brachytherapy with EBRT to treat these patients. This approach has resulted in excellent disease control rates (Table 3) . At Mount Sinai, using an approach that involves 9 months of hormonal therapy, 103-Pa brachytherapy and external beam irradiation, the 7-year biochemical control rate was 83% for 360 patients with high-risk prostate cancer. 54 Dattoli et al 55 reported on 243 patients with high-risk disease treated with combination therapy and showed an 80% biochemical control rate at 13 years. These excellent rates compare favorably to those with radical prostatectomy, especially when one focuses on the subset of patients with high-grade tumors (Gleason score 8 -10) . At Mount Sinai patients with a Gleason score of 8 -10 had a 77.5% freedom from PSA failure (FFPF) rate at 7 years. 54 This appears to be superior to the 10% to 39% rate found after radical prostatectomy alone. 58, 59 
IMPORTANCE OF IMPLANT QUALITY
When transperineal ultrasound-guided prostate brachytherapy began to be implemented into clinical practice in the late 1980s, limited data were available to guide physicians in determining the appropriate prescription dose for I-125 seed implants. At that time, the commonly used prescription dose of 160 Gy was derived from the original work done by Hilaris at Memorial Sloan Kettering Cancer Center, where 160 Gy was chosen as the dose to be delivered by permanent I-125 seed prostate implants. 60 Although this dose was empirically derived, it was felt to be equivalent to a dose of 67 Gy of EBRT delivered over 7 weeks based on timedose factor calculations. 61, 62 This dose was selected at a time when it was believed that doses of 65-70 Gy of EBRT provided excellent local control based on the subsequent digital rectal examination evaluations. [63] [64] [65] There were significant problems underlying the assumptions that led to the dose choice of 160 Gy for prostate implants. We now know that traditional doses of 65-70 Gy of EBRT have not achieved the high rate of local control as previously reported using digital rectal examination, based on high reported PSA failure rates and positive post-treatment biopsy results after EBRT. 66 -68 The assumption that the doses calculated from the original Memorial Sloan Kettering Cancer Center prostate implant experience using a matched peripheral dose technique were the actual doses received by the prostate is questionable, because the isodose lines calculated around the seeds could not be correlated to the actual position of the prostate gland. Finally, the assumption that 160 Gy of I-125 is biologically equivalent to 70 Gy of external beam irradiation based on time-dose factor calculations is now known to probably not be true, based on the more commonly used biologically effective dose (BED) calculations. 69 Mount Sinai reported the first dose-response analysis for permanent prostate brachytherapy in the modern PSA era. The parameter chosen to measure dose was the dose to 90% of the prostate gland or D90, which was derived from the 1-month postimplant dosimetric computed tomographybased dose volume histogram. This analysis showed a clear dose response, with improved biochemical control associated with increased dose. When patients were separated into 2 groups-those with D90 values less than 140 Gy and those with D90 values Ն140 Gy-there was a large difference in biochemical control rates (68% vs 92% at 4 years, P ϭ 0.02) favoring the higher doses. In multivariate analysis, dose was the most significant predictor of outcome. 70 Higher prostate doses were also found to affect local control defined by a negative post-treatment prostate biopsy. Patients with postimplant D90 values for I-125 of Ͻ120 Gy had a negative biopsy rate of 69% compared with 96% in those with a D90 values Ͼ180 Gy. Patients treated with Pd-103 showed a similar effect. D90 values Ͻ80 Gy were associated with a 79% negative biopsy rate compared with 0% positive biopsy with D90 values Ͼ120 Gy. 71 Other investigators have validated this dose-response relationship. Potters et al 72 found a dose-response relationship for I-125 implants and Pd-103 implants combined with EBRT. The dose parameter that demonstrated the response was the D90. With a median follow-up of 30 months, a D90 dose-response cutoff value Ͼ90% of the prescribed dose was identified. Prostate implants with a D90 dose Ͻ90% had an 80.4% 4-year PSA-relapse free survival, whereas those with a D90 dose Ͼ90% had a 92.4% 4-year PSA-relapse free survival (P ϭ 0.001). No cutoff value was found for the V100 and D100 dose that predicted for PSA failure. Wallner et al 47 in a randomized trial testing the effect of Pd-103 versus I-125 in the treatment of low-risk prostate cancer found a doseresponse relationship. Those patients receiving a D90 Ͼ100% of the prescription dose had a 98% freedom from PSA failure versus 82% for those with D90 Ͻ100%.
Zelefsky et al 32 reported on a multi-institutional analysis of patients treated with brachytherapy monotherapy. Of these patients, 1,831 (68%) were treated with I-125 seed implantation, and median follow-up was 63 months. Among patients with D90 values Ͼ130 Gy, the 8-year PSA relapsefree survival was 93% compared with 76% for those with lower D90 dose levels (P Ͻ 0.001). When a multivariate analysis was performed on patients with available postimplantation dosimetric information, D90 emerged as a significant predictor of biochemical outcome (P ϭ 0.01). It has often been difficult to compare different types of brachytherapy regimens in terms of dose because different isotopes with different prescription doses, half-lives, and dose rates have been used. In addition, some regimens add external beam irradiation, with very different fractionation schemes into the mix. To compare these different regimens, Stock et al 69 converted doses from different isotopes and regimens into a single value for each patient by using BED equations based on the D90 values and external beam doses and fractionations. BEDs had a significant impact on PSA failure rates. There was a significant improvement in FFPF rates with increasing BEDs. The 10-year FFPF for the BED groups Ͻ100, Ͼ100 -120, Ͼ120 -140, Ͼ140 -160, Ͼ160 -180, Ͼ180 -200, and Ͼ200 were 46%, 68%, 81%, 85.5%, 90%, 90%, and 92%, respectively (P Ͻ 0.0001). Dichotomizing the data on the basis of the above findings into 2 BED groups-Ͻ150 (169 patients) and Ͼ150 (1,152 patients)-revealed FFPF rates at 10 years of 69% and 91%, respectively (P Ͻ 0.0001). In addition, in multivariate analysis, BED was the most significant factor to affect biochemical failure rates. Stone et al 74 reported outcomes from a multi-institutional (6 centers) data set. This analysis of 3,928 patients treated with brachytherapy and with postimplant dosimetry demonstrated a dose-response relationship using BED equations. Patients were divided into dose groups on the basis of D90 values. There were 3 dose groups: low-dose (Ͻ140 BED), intermediate-dose (140 -200 BED), and high-dose (Ͼ200 BED). There was a dose-response seen within disease risk groups. Using the American Society for Therapeutic Radiation Oncology (ASTRO) definition of PSA failure, 10-year PSA disease-free survival rates for low-risk patients were 69.8%, 86%, and 88.1% for low-, intermediate-and high-dose groups, respectively (P Ͻ 0.0001). For intermediate-risk patients, the rates were 52.9%, 74%, and 94.3% for low-, intermediate-, and high-dose groups, respectively (P Ͻ 0.0001). For highrisk patients, the rates were 19.2%, 61.8%, and 90%, respectively (P Ͻ 0.0001).
DISTANT METASTASES AND CANCER-SPECIFIC SURVIVAL
Local disease control should be achieved with brachytherapy in most patients with prostate cancer. The data from several studies indicate that it can, but only under certain conditions and if specific treatment targets are met. Treatment failure in the patients with prostate cancer has typically been determined by a rising PSA value or cause-specific mortality. Local control, however, has been determined by digital rectal examination and by prostate biopsy. The former is not typically used anymore because of its inaccuracy. The latter, although controversial as relating to the true significance of a postimplant "positive biopsy," has been more thoroughly investigated. The 2 major controversial issues that persist are the pathologic interpretation of the tissue in cases of "indeterminate results" and the long-term significance of positive biopsy results.
Several investigators have reported their postimplant biopsy results in 3 classifications: negative, positive, and indeterminate. 75, 76 Crook 76 found that the proportion of inde-terminate biopsies decreased over time from 33% at 1 year to 7% by year 4. Histologically, these patients have residual prostate cancer in the specimens with "marked radiation effect." Whereas most have considered these classifications nonviable, until recently there have been no long-term studies that have followed these patients and documented eradication or progression of the disease.
Stone et al 77 recently reported the long-term patterns of local failure in 508 men who agreed to have a prostate biopsy a minimum of 2 years postimplant. The overall local failure by biopsy was 7.7%. Patients with higher radiation doses had a local failure rate of 3.6% versus 12.5% for low-risk (P Ͻ 0.001), 5.7% versus 14% for intermediate-risk (P ϭ 0.039), and 4.5% versus 18.8% for high-risk (P ϭ 0.035) disease. For the individual isotopes, to constitute a high dose, a D90 of at least 160 Gy for I-125 or 124 Gy for Pd-103 or the use of combination therapy had to be delivered. In patients receiving combination therapy, the higher-dose patients received 45 Gy of EBRT and a minimum of 100 Gy of Pd-103. In addition, hormone therapy appeared to further improve the biopsy results from 11.8% to 3.3% positive in patients with both intermediate-and high-risk disease who received the higher doses (P ϭ 0.087).
In this study, routine prostate biopsies were offered at 2 years post-therapy regardless of disease status and 10% (52 of 508) had positive biopsy results. In 44% of these patients, results eventually reverted to negative. This finding is in contrast to the report of Prestidge et al 75 of 22% positive or "indeterminate" results after 1 year. 75 Almost all of the positive 2-year biopsy results in our patients demonstrated the same results. Whereas Prestidge et al believed that most of these positive results would "clear" with time (although this was not actually demonstrated in their study), our data suggest that this happens less than half the time. These data can present a conundrum for the urologist who elects to perform a biopsy on patients 2 years after brachytherapy. Although biopsies are not routinely performed in clinical practice, the decision to perform a biopsy after brachytherapy may be made if the patient experiences a rise in PSA value after reaching a nadir. Unfortunately, up to 31% of patients can experience a temporary rise in PSA value after brachytherapy, which is not associated with either local or systemic disease progression. 78, 79 Our suggestion would be to observe these patients and not perform a biopsy if the D90 is Ͼ100%. If the patient experiences several consecutive PSA elevations, a biopsy may become necessary.
The 10-year FFPF was 80% if the biopsy results were negative versus 27.3% if results of the final biopsy were positive (P Ͻ 0.0001). The significance of positive postirradiation biopsy results has been controversial in the past. The study of Stone et al, 77 with long follow-up and repeat biopsies, confirms that persistently positive biopsy results lead to disease progression. In fact, positive biopsy results were 18.5 times more likely to result in deaths from prostate cancer than negative results (P Ͻ 0.0001).
Stock et al 78 has also described the effect of the BED on biopsy outcomes. The D90 values were converted into a BED for each isotope, which was summed with the BED of EBRT for patients receiving combination therapy. This allowed comparisons of treatment factors to one dose equivalent when factors influencing the biopsy outcomes were evaluated. Multivariate analysis revealed that only hormone therapy (P ϭ 0.05) and BED (P ϭ 0.006) had significant influences on biopsy results. Table 4 lists the published studies detailing biopsy results after brachytherapy.
TREATMENT-RELATED SIDE EFFECTS
The side effect profile for most men who undergo brachytherapy monotherapy is relatively benign. The majority of patients will be able to urinate immediately after the procedure. Urinary obstruction does occur at a rate of approximately 5% although its occurrence mostly depends on the patient's preimplant urinary symptoms. 81 Complete retention is related to obstructive uropathy and correlates with elevated American Urology Association scores. 82 Immediately after the implant the patient may notice blood in the urine, which should clear after the first few voiding attempts. If the patient attempts sexual relations in the immediate postbrachytherapy period, it is possible that a seed may be ejaculated; therefore, it is recommended that patients use a condom within the first several months after the procedure. Hematospermia may also occur for some time after the implant. 83 Within a few weeks most men will begin to experience urinary symptoms. The severity and nature of these symptoms can vary dramatically although the majority of men will have increased frequency and urgency. If these symptoms are troublesome, ␣-blockers and anti-inflammatory medications such as ibuprofen typically offer some relief. Burning or dysuria can be managed by urinary analgesics (Pyridium) and by decreasing acid in the diet. These symptoms may take 6 months to resolve. 84, 85 Rectal symptoms may also occur and typically accompany the urinary symptoms. Presumably, inflammation in the prostate is causing inflammation to the rectal mucosa. Constipation can exacerbate the discomfort; therefore, a bulkproducing laxative and use of anti-inflammatory medication are often recommended. Minor proctitis occurs in approximately 10% to 20% of patients and is dose and technique dependent. 86, 87 It is best managed conservatively also with a bulk-producing laxative without further intervention. If it persists, a steroid-containing suppository can be added. Aggressive management by rectal wall biopsy or fulguration (or other caustic therapy) should be strictly avoided as this therapy has been reported to be one of the main treatments associated with ulcer and fistula formation. The rectal mucosa next to the prostate often gets a very high dose of radiation, leading to fibrosis and decreased vascularity of the submucosa and rectal wall. Laser or cautery therapy or aggressive rectal examination can result in permanent injury, leading to a prostate-rectal fistula. Subsequent management of this complication may include early bowel diversion, hyperbaric oxygen treatment, urinary diversion with a suprapubic tube and resection of the affected tissues with construction of a neobladder and a coloanal reanastomosis. In some cases, a small fistula has been successfully managed with urethral catheter drainage. This is a rare complication, which has occurred in approximately 1 in 1,000 patients. 88, 89 Erectile dysfunction is a common consequence of aging and had been very difficult to quantify accurately in patients sent for radiotherapy because this group has, for the most part, been older than 65 years. Commonly quoted incidence rates of erectile dysfunction after brachytherapy range from 20% to 40%, usually several years after the therapy. 90 -92 A recent study from Mount Sinai of 131 men with optimal erectile function before prostate brachytherapy and followed for a minimum of 7 years showed that the patient's age significantly influenced potency preservation. A 50-year-old man had a 92% likelihood of maintaining erectile function compared with 64% and 58% for the patient in his 60s or 70s, respectively. 93 These age-related data are similar to those found for patients undergoing radical prostatectomy.
There is a risk of secondary malignancy risk with all exposures to radiotherapy. This is a stochastic phenomenon, which means that the incidence appears to be random. The pediatric population has the greatest risk for a clinically meaningful increase in secondary malignancies after exposure to radiotherapy. In the population older than 40 years, it is possible to measure, on the basis of large epidemiologic studies, an increased malignancy rate among those exposed to radiotherapy. Regarding brachytherapy specifically, a single institution data set found that among 348 patients followed for a median of 10.8 years an excess of 35 cancers per 10,000 patients was seen after the brachytherapy procedure. 94 Although this incidence is statistically significant, the authors felt that the incidence had little clinical meaning. In addition, the risk of bladder and colorectal cancer was 1.6% in the brachytherapy alone group versus 5.8% in the brachytherapy plus supplemental radiotherapy group (P ϭ 0.06) with a trend toward significance. A larger Surveillance Epidemiology and End Results (SEER)-Medicare database search of men with the diagnosis of prostate cancer from 1973 to 1999 identified 95 The study was limited to men who were alive 5 years after the initial diagnosis and showed that of the final study population of 140,767 men, those receiving EBRT had a small but statistically significant risk of a secondary cancer whereas those treated with an implant alone or in combination with EBRT radiotherapy did not have an increased risk of secondary cancers. Another interesting recent study, also from the SEER database, looked at men with the diagnosis of prostate cancer from 1973 to 2001 as their first carcinoma, identifying 237,772 patients. 96 These were divided into 3 groups, those who had surgery, radiotherapy, or conservative management. It was found that men having the surgery had the lowest incidence of rectal cancer, and men with conservative management had the highest incidence of rectal cancer. In an interesting letter to the editor regarding the article, David Brenner 97 put forth evidence that there is a known higher incidence of smoking among men conservatively treated for prostate cancer in Canada and that furthermore this incidence in smoking could be the causal factor behind the increased incidence in rectal cancer in the untreated group. In addition, he described a possible association between a low testosterone environment and a causal association to the onset of rectal cancer. On the basis of the work done so far, it is possible to conclude that the rate of secondary cancers after brachytherapy is very small and clinically insignificant.
GENETIC PREDICTORS OF SIDE EFFECTS
A compelling body of work regarding the potential of genetic testing to predict possible side effects is now being recognized. In a series of studies in breast cancer and prostate cancer, a relationship has been found between the incidence of radiotherapy-induced fibrosis and the expression of the ataxiatelangiectasia mutation (ATM) gene. 98 In breast cancer, heterozygosity in the ATM gene manifests as telangiectatic skin changes and subcutaneous fibrosis. 99 In men treated with I-125 brachytherapy for prostate cancer, the same profibrotic mechanisms are related to erectile dysfunction, late rectal bleeding, and urinary bother. Among men treated with prostate brachytherapy, the initial results of an association between erectile dysfunction and ATM status of the pilot study of 37 men has been validated in a new group of 98 additional men. 100, 101 In addition, of note, a larger study of 108 men whose ATM status was clarified showed that in the low dose range of rectal exposure those men with ATM heterozygosity accounted for almost all of those who had late proctitis. 102 These initial findings have led to significant associations in other important molecules and the late effects of radiotherapy. In the future, as the cost of genetic screening continues to fall, one may be able to predict with a reasonable degree of certainty not only whether a patient will experience any side effect from brachytherapy or EBRT but possibly also which side effect and its severity. This information will certainly add to the armamentarium of knowledge that a counseling physician will be able to give to the patient to facilitate the best possible outcome of prostate cancer treatment.
CONCLUSION
Prostate brachytherapy is an excellent treatment modality for localized prostate cancer. The major side effects are temporary urinary symptoms. In the future, we will most probably be able to better inform patients about their specific risks of side effects, thereby decreasing substantially the influence of any given physician's therapeutic bias in the face of several reportedly equivalent therapies.
